We don't know whether the most recent response to this request contains information or not – if you are BEN HOLDSWORTH please sign in and let everyone know.

Breast Cancer Treatment

We're waiting for BEN HOLDSWORTH to read recent responses and update the status.

Dear Royal Berkshire NHS Foundation Trust,

I would like to please request the following information with regards to Breast Cancer Treatment, on behalf of Novartis.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
• Abemaciclib (Verzenios) + aromatase inhibitor *
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
• Alpelisib (Piqray) + Fulvestrant (Faslodex)
• Atezolizumab (Tecentriq)**
• Bevacizumab (Avastin)
• Eribulin (Halaven)
• Everolimus (Afinitor) + Exemestane
• Fulvestrant (Faslodex) as a single agent
• Gemcitabine + paclitaxel
• Herceptin (Trastuzumab) + paclitaxel
• Herceptin (Trastuzumab) as a single agent
• Lapatinib (Tyverb)
• Neratinib (Nerlynx)
• Olaparib (Lynparza)
• Palbociclib (Ibrance) + aromatase inhibitor*
• Palbociclib (Ibrance) + Fulvestrant (Faslodex)
• Pertuzumab (Perjeta) + trastuzumab + docetaxel
• Ribociclib (Kisqali) + aromatase inhibitor*
• Ribociclib (Kisqali) + Fulvestrant (Faslodex)
• Talazoparib (Talzenna)
• Trastuzumab emtansine (Kadcyla)
• Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

Sincerely thank you for taking the time to answer these questions.

Yours faithfully,
Ben Holdsworth

FOI, Royal Berkshire NHS Foundation Trust

Dear Requester,

We acknowledge your enquiry under the Freedom of Information Act.  I will
look into your request and respond within 20 working days from receipt of
your request.

Yours sincerely,

Freedom Of Information Team
Royal Berkshire NHS Foundation Trust
Tel: 0118 322 6743/7405
Email: [Royal Berkshire NHS Foundation Trust request email]

══════════════════════════════════════════════════════════════════════════

show quoted sections

FOI, Royal Berkshire NHS Foundation Trust

Dear Ben Holdsworth,
 
Further to your request please see the Trust's response below.
 
Kind regards,
FOI and Policy Officer
 
Royal Berkshire
NHS  Foundation Trust
Level 4
Main Entrance, Craven Road
Reading, Berkshire
RG1 5AN
 Natasha Tucker
FOI and Policy Officer
 
Tel: 0118 322 5111
Email: [1][email address]
Web: [2]www.royalberkshire.nhs.uk
 

show quoted sections

We don't know whether the most recent response to this request contains information or not – if you are BEN HOLDSWORTH please sign in and let everyone know.